Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Volition Announces Detection of Over 95% of Early-Stage Cancers

Wednesday, March 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx Limited has announced promising proof of concept data demonstrating its Capture-Seq™ technology's ability to detect over 95% of early-stage cancers. This breakthrough could revolutionize cancer diagnosis, offering a significant advancement in early detection methods. The announcement was made by Dr. Jake Micallef, the Chief Scientific Officer of Volition.
Price reaction · baseline $4.022 (2026-03-24 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close
-4.9%
day 1
-4%
day 3
-5.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Detection of over 95% of early-stage cancers.
  • Breakthrough technology with promising proof of concept.
  • Potential to significantly impact cancer diagnosis.

Full Press Release Details

HENDERSON, Nev.,March 25, 2026/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture-Seq™ technology.

Dr. Jake Micallef

, Chief Scientific Officer, Volition, commented:

Frequently Asked Questions

What is Capture-Seq™ technology?

Capture-Seq™ is a breakthrough technology developed by Volition for cancer detection.

How effective is the new cancer detection method?

The method detects over 95% of early-stage cancers according to recent data.

Who is the Chief Scientific Officer of Volition?

Dr. Jake Micallef is the Chief Scientific Officer at Volition.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx Capture-Seq cancer detection early-stage cancer
Last updated: Mar 25, 2026

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk